Urabe et al[22]. (2002)
|
Three-Bac
|
2
|
GFP
|
200mL
|
2x106 a
|
4.5x104±
0.32x104 b
|
NA
|
NA
|
NA
|
NA
|
NA: 1344:1c
±283
|
First report of rAAV production in sf9 cells
|
Meghrous et al[48]. (2005)
|
Three-Bac
|
2
|
GFP
|
3L
20L
|
3.08x106 a
1.7x106 a
|
NA
|
NA
|
132
253
|
4.09x108 b d
4.46x108 b d
|
6.7x1011 b e
3.71x1011 b e
|
1640: NA: 1
830: NA: 1
|
Bac-Rep MOI optimization and demonstration of AAV production process
scalability in bioreactor
|
Urabe et al [42]. (2006)
|
Three-Bac
|
5
|
hGFP
|
NA
|
NA
|
5.6x104±
0.32x104 f
7.67x104 ±
2.12x104 g
|
NA
|
NA
|
NA
|
NA
|
NA
|
Bac-Cap modification, VP1 Domain swapping to produce functional AAV5
vector particle
|
Aucoin et al[55]. (2006)
|
Three-Bac
|
2
|
GFP
|
20mL
|
NA
|
NA
|
2x1010
2x109
|
NA
|
5x107 d
1.7x108 d
|
NA
|
3400:400:1
3000:12:1
|
BacITR: BacRep: BacCap (1:9:1)
BacITR: BacRep: BacCap (9:9:9)
|
Nagrete and Kotin[69] (2007)
|
Three-Bac
|
2
|
GFP
|
200mL
5L-Wave™
20L-Wave™
10L-STB
40L-STB
|
2x106 a
|
NA
|
~3x1010 b
~ 9x109 b
~5x109 b
~2x1010 b
~4.33x1010 b
(±4.1x1010)
|
NA
|
~1x109 h
~5x108 h
~3x108 h
~5x108 h
~7.5x108 h
(±2.5x108)
|
NA
|
NA: 30:1
NA: 18:1
NA: 16:1
NA: 40:1
NA: 20:1
|
Three-Bac system with a modified Bac-Cap sequence. Demonstration of AAV
process scalability at large scale
|
Aucoin et al [68].
(2007)
|
Three-Bac
|
2
|
GFP
|
NA
|
NA
|
~12000
|
NA
|
200d
|
4x108
|
NA
|
4600:79:1
|
Temperature modulation study and its effect on AAV yield
|
Mena et al[59]. (2010)
|
Three-Bac
|
2
|
GFP
|
20mL
3L
|
9.43x106 i
9.5x106 i
|
NA
|
1.17x1011 b
2.2x1011 b
|
NA
|
2.9x109 b d
(±0.32x109)
2.35x109 b d
|
NA
|
NA: 40:1
NA: 94:1
|
Low MOI, Fedbatch production
|
Liu et al [50]. (2010) |
Three-Bac |
2 |
GFP |
50mL |
1x106
|
NA |
NA |
240 |
2.4x108
|
NA |
NA |
AAV production in Sf21 cells in fed-batch culture |
Cecchini et al[57]. (2011)
|
Three-Bac
|
9
8
6
|
GFP
U7smOPT
GFP
U7smOPT
PLS
|
10L
20L
100L
200L
20L
|
3.55x106 i
3.23x106 i
3.88x106 i
4.29x106 i
(±1x106)
4.41x106 i
3.44x106 i
|
2.24x104
2.41x104
1.48x104
2x104
(±0.3x104)
1.82x104
2.07x104
|
7.9x1010 b
7.8x1010 b
4.44x1010 b
8.75x1010 b
(±4.04x1010)
7.45x1010 b
5x1011 b
|
NA
|
NA
|
NA
|
NA
|
AAV production employing BIIC strategy. Demonstration of AAV production
process robustness at bioreactor scale regardless of the type of
transgene
|
Chen[33]. (2008)
|
Three-Bac
Two Bac
BacInRep/Cap
|
2
6
8
1
2
|
GFP
GFP
GFP
GFP
GFP
|
NA
|
5x106 a
5x106 a
5x106 a
5x106 a
5x106 a
|
NA
|
1.37x1011 b
(±0.34x1011)
3.53x1010 b
9.65x1010 b
4.41x1010 b
2.2x1011
|
NA
|
NA
|
NA
|
NA
|
Bac-Intron constructs of baculovirus vector
Baculovirus with enhanced passage dependent stability
Bac-In-Rep/Cap and Bac-In-ITR
|
Smith et al. [34]. (2009)
|
Two-Bac
BacRep2CapX
|
1
2
|
GFP
GFP
|
200mL
200mL
|
2.4x106 a
1.2x106 a
|
NA
|
1.07x1013 j
(±0.46x1013)
6.5x1012 j
|
NA
|
5.08x1010 j k
(±5.9x1010)
1.9x1010 j k
|
NA
|
NA: 200:1
NA: 350:1
|
Bac-Rep/Cap and Bac-ITR based two baculovirus vectors with improved
stability
|
Aslanidi et al[35]. (2009)
|
One-Bac 1.0
|
2
1
|
GFP
GFP
|
NA
|
NA
|
1.4x105
7.3x104
|
NA
|
NA
|
NA
|
NA
|
NA
|
Inducible packaging Sf9 cell line for AAV production
|
Mietszch et al[39]. (2014)
|
One-Bac 1.0
|
1-11
12
|
GFP
GFP
|
NA
|
NA
|
~104-105 l
~103 l
|
NA
|
NA
|
NA
|
NA
|
NA
|
Production of all AAV serotypes employing One-Bac system
|
Mietszch et al[45]. (2015) |
One-Bac 2.0 |
5 |
GFP |
NA |
NA |
1x105 l
|
NA |
NA |
NA |
NA |
NA |
One-Bac system with
VP ratio restoration to improve AAV5 vector functionality |
Joshi et al [58].
(2019)
|
One-Bac 3.0
|
5
|
GFP
|
25mL
3L
|
12x106 i
12x106 i
|
3x104± 0.4x104
2.7x104
|
2.7x1011 b
(±0.37x1011)
3.8x1011 b
(±0.53x1011)
|
20±5
22±5
|
1.9x108 b m
(±0.43x108)
2.1x108 b m
(±0.48x108)
|
ND
|
9600n: 2400:1
9400n: 2500:1
|
Robust, High MOI, Fedbatch AAV5 production process. Process validation
at bioreactor scale. Improved volumetric yield of genomic and functional
AAV5 vector
|
Yang et al [70].
(2019)
|
One-Bac 3.0+
|
2
8
9
|
GFP
GFP
GFP
|
NA
|
2x106
2x106
2x106
|
1.35x105 ±0.46x105
2.16x105 ±0.53x105
1.80x105 ±0.39x105
|
NA
|
NA
|
NA
|
NA
|
NA
|
One-Bac based Rep2 expressing transformed Sf9 cell line.
Offer more flexibility for the production of multiple AAV serotypes
production
|